Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Med Clin (Barc) ; 2024 Jan 25.
Article in English, Spanish | MEDLINE | ID: mdl-38278759

ABSTRACT

INTRODUCTION: To reach the diagnosis of giant cell arteritis (GCA), signs, symptoms, laboratory tests, imaging findings, and occasionally anatomopathological results from temporal artery biopsy are evaluated. This study describes the results of an algorithm analysis based on clinical and ultrasound evaluation of patients with suspected GCA, highlighting its diagnostic utility by contrasting its use in different clinical suspicion scenarios. METHOD: Prospective multicenter study evaluating patients referred with suspected GCA through a preferential circuit (fast track), grouping them according to low or high clinical suspicion of GCA. Each of these scenarios is evaluated by biopsy and ultrasound for all patients, resulting in positive, indeterminate, or negative outcomes, yielding six possible groups. Potential areas of improvement are explored, emphasizing that, following a negative or indeterminate ultrasound, 18-FDG-PET-CT could be recommended. We analyze the results and application of a diagnostic algorithm, confirming its efficiency and applicability based on whether there is high or low clinical suspicion. RESULTS: Sixty-nine patients (41 in the high suspicion group and 28 in the low suspicion group). There were 41 new diagnoses of GCA: 35 in the high suspicion group and 6 in the low suspicion group. Using ultrasound alone, the initial algorithm has an overall diagnostic efficiency of 72.5%, which improves to 80.5% when including 18F-FDG-PET/CT. The negative predictive value of ultrasound in patients with low clinical suspicion is 84.6%, and the positive predictive value of ultrasound in patients with high suspicion is 100%, improving sensitivity from 57.1% to 80.8% with 18F-FDG-PET/CT in this scenario. Temporal artery biopsy was performed on all patients, with no differences in sensitivity or specificity compared to ultrasound. In cases where all three tests - ultrasound, biopsy, and 18F-FDG-PET/CT - are performed, sensitivity increases to 92.3% in patients with high clinical suspicion. CONCLUSION: In situations of high clinical suspicion, the algorithm provides sufficient information for the diagnosis of GCA if ultrasound is positive. A negative ultrasound is sufficient to rule out the diagnosis in the context of low clinical suspicion. 18-FDG-PET-CT may be useful in patients with high suspicion and negative or indeterminate ultrasound results.

2.
Bone ; 168: 116654, 2023 03.
Article in English | MEDLINE | ID: mdl-36584785

ABSTRACT

OBJECTIVES: To estimate the incidence of clinical fragility fractures in postmenopausal women with rheumatoid arthritis (RA) and analyze risk factors for fracture. METHODS: Incidence of clinical fragility fractures in 330 postmenopausal women with RA was compared to that of a control population of 660 age-matched postmenopausal Spanish women. Clinical fractures during the previous five years were recorded. We analyzed associations with risk factors for fracture in both populations and with disease-related variables in RA patients. RESULTS: Median age of RA patients was 64 years; median RA duration was eight years. Sixty-nine percent were in remission or on low activity. Eighty-five percent had received glucocorticoids (GCs); 85 %, methotrexate; and 40 %, ≥1 biologic DMARD. Fifty-four patients and 47 controls had ≥1 major osteoporotic fracture (MOF). Incidence of MOFs was 3.55 per 100 patient-year in patients and 0.72 in controls (HR: 2.6). Risk factors for MOFs in RA patients were age, previous fracture, parental hip fracture, years since menopause, BMD, erosions, disease activity and disability, and cumulative dose of GCs. Previous fracture in RA patients was a strong risk for MOFs (HR: 10.37). CONCLUSION: Of every 100 postmenopausal Spanish women with RA, 3-4 have a MOF per year. This is more than double that of the general population. A previous fracture poses a high risk for a new fracture. Other classic risk factors for fracture, RA disease activity and disability, and the cumulative dose of GCs are associated with fracture development.


Subject(s)
Arthritis, Rheumatoid , Osteoporotic Fractures , Humans , Female , Middle Aged , Case-Control Studies , Postmenopause , Incidence , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/epidemiology , Osteoporotic Fractures/etiology , Risk Factors , Bone Density
3.
Med. clín (Ed. impr.) ; 153(4): 151-153, ago. 2019. ilus, tab
Article in Spanish | IBECS | ID: ibc-183446

ABSTRACT

Fundamento y objetivo: La arteritis de células gigantes (ACG) es la vasculitis sistémica más frecuente en adultos. En los últimos años, existe un interés creciente en evaluar la utilidad de la ecografía de arterias temporales superficiales (EATS), que permite valorar la inflamación de la pared vascular. Material y métodos: Estudio de cohorte observacional y descriptivo de 120 EATS a 60 pacientes con sospecha clínica de ACG según criterios clásicos de ACR (American College of Rheumatology). Resultados: De todos los pacientes a quienes se les realizó la EATS, el 42,3% presentó diagnóstico de ACG según los criterios de clasificación ACR. La sensibilidad y la especificidad de la ecografía en nuestra cohorte de pacientes con alta sospecha clínica fueron de 81,8 y 93,3%, respectivamente, con un VPP de 90,1% y un VPN de 87,5%. Conclusión: Los resultados avalan la ecografía de arteria temporal bilateral como una técnica útil, indolora, rápida, accesible, de alta especificidad y amplia validez diagnóstica


Background and objective: Giant cell arteritis (GCA) is the most frequent systemic vasculitis in adults. In recent years, the usefulness of temporal artery ultrasound (TAUS) as a diagnostic tool to assess the underlying inflammation of the vascular wall during the inflammatory process has been under clinical investigation. Material and methods: Observational and descriptive cohort study of 120 TAUS in 60 patients with clinical suspicions of GCA, according to the ACR (American College of Rheumatology) classification criteria. Results: Among all patients who underwent ultrasound, 42.3% met clinical criteria for GCA according to ACR. Sensitivity and specificity of TAUS in our cohort with clinical suspicion was 81.8% and 93.3%, respectively. A PPV of 90.1% and a VPN of 87.5% were observed. Conclusion: Our results showed that TAUS as a useful, indolent, fast, and accessible tool with high diagnostic specificity and diagnostic value


Subject(s)
Humans , Male , Female , Giant Cell Arteritis/diagnostic imaging , Ultrasonography, Doppler/methods , Temporal Arteries/diagnostic imaging , Mass Screening/methods , Risk Factors , Giant Cell Arteritis/classification , Glucocorticoids/therapeutic use
4.
Med Clin (Barc) ; 153(4): 151-153, 2019 08 16.
Article in English, Spanish | MEDLINE | ID: mdl-29871775

ABSTRACT

BACKGROUND AND OBJECTIVE: Giant cell arteritis (GCA) is the most frequent systemic vasculitis in adults. In recent years, the usefulness of temporal artery ultrasound (TAUS) as a diagnostic tool to assess the underlying inflammation of the vascular wall during the inflammatory process has been under clinical investigation. MATERIAL AND METHODS: Observational and descriptive cohort study of 120 TAUS in 60 patients with clinical suspicions of GCA, according to the ACR (American College of Rheumatology) classification criteria. RESULTS: Among all patients who underwent ultrasound, 42.3% met clinical criteria for GCA according to ACR. Sensitivity and specificity of TAUS in our cohort with clinical suspicion was 81.8% and 93.3%, respectively. A PPV of 90.1% and a VPN of 87.5% were observed. CONCLUSION: Our results showed that TAUS as a useful, indolent, fast, and accessible tool with high diagnostic specificity and diagnostic value.


Subject(s)
Giant Cell Arteritis/diagnostic imaging , Temporal Arteries/diagnostic imaging , Ultrasonography, Doppler , Female , Giant Cell Arteritis/epidemiology , Humans , Male , Middle Aged , Sensitivity and Specificity
5.
Reumatol. clín. (Barc.) ; 13(6): 354-356, nov.-dic. 2017. ilus
Article in Spanish | IBECS | ID: ibc-167212

ABSTRACT

Los pacientes con artritis reumatoide (AR) tratados con fármacos modificadores del curso de la enfermedad están expuestos a desarrollar infecciones potencialmente graves como la leishmaniasis. L. infantum es endémica en el Mediterráneo, hecho que obliga ante un paciente con AR que presenta fiebre y pancitopenia, a descartar este proceso. Un diagnóstico de sospecha precoz, puede evitar un curso y pronóstico fatal (AU)


Patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs are susceptible to severe infections such as leishmaniasis. As L. infantum is endemic in the Mediterranean region, it is necessary to rule this infectious process out in any RA patient presenting with fever and pancytopenia. An early diagnosis based on a high suspicion can prevent a fatal outcome (AU)


Subject(s)
Humans , Female , Middle Aged , Leishmaniasis, Visceral/complications , Arthritis, Rheumatoid/drug therapy , Methotrexate/therapeutic use , Hydroxychloroquine/administration & dosage , Glucocorticoids/administration & dosage , Amphotericin B/administration & dosage , Prognosis , Comorbidity , Diagnosis, Differential , Early Diagnosis
6.
Clin Chim Acta ; 475: 169-171, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29056531

ABSTRACT

At present, data comparing the quantification methods for measurement of free vitamin D (direct assay [direct 25-OHDF] and estimated by calculation [calculated 25-OHDF]), are scarce. The aim of this study was to analyse the concordance between these two methods of 25-OHDF analysis (direct vs. calculated). METHODS: Serum values of total 25-OHD (25-OHDT), vitamin D binding protein (DBP) (by R&D Systems ELISA), calculated 25-OHDF (by DBP, albumin and 25-OHDT) and direct 25-OHDF (by DIAsource ELISA) were analysed in 173 healthy women (aged 35-45years). Assessment of concordance was evaluated by the Bland-Altman plot and the total deviation index (TDI). RESULTS: The mean values of calculated and direct 25-OHDF in these subjects were 5.27±2.5 and 3.83±1.01pg/mL, respectively. We found significantly lower values of 25-OHDF on comparing subjects with and without vitamin D deficiency, independently of the method used. The total deviation index evaluated by the Bland-Altman plot showed low concordance for both measurements. Only low 25-OHDF levels were concordant. CONCLUSIONS: This study shows that the concordance between these two methods of 25-OHDF analysis is low and has a concentration dependent bias. Further studies are necessary to clarify the reference values and the indications for 25-OHDF measurement.


Subject(s)
Calcifediol/blood , Enzyme-Linked Immunosorbent Assay/standards , Vitamin D Deficiency/blood , Adult , Female , Humans , Middle Aged , Regression Analysis , Reproducibility of Results , Vitamin D Deficiency/diagnosis , Vitamin D-Binding Protein/blood
7.
Reumatol Clin ; 13(6): 354-356, 2017.
Article in English, Spanish | MEDLINE | ID: mdl-27523470

ABSTRACT

Patients with rheumatoid arthritis (RA) treated with disease-modifying antirheumatic drugs are susceptible to severe infections such as leishmaniasis. As L. infantum is endemic in the Mediterranean region, it is necessary to rule this infectious process out in any RA patient presenting with fever and pancytopenia. An early diagnosis based on a high suspicion can prevent a fatal outcome.


Subject(s)
Arthritis, Rheumatoid/complications , Immunosuppressive Agents/adverse effects , Leishmaniasis, Visceral/etiology , Methotrexate/adverse effects , Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Disease Susceptibility , Early Diagnosis , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Indomethacin/therapeutic use , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/drug therapy , Methotrexate/therapeutic use , Middle Aged , Pancytopenia/chemically induced , Prednisone/adverse effects , Prednisone/therapeutic use
8.
Clin Rheumatol ; 35(10): 2463-8, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27567630

ABSTRACT

The aim of this study was to assess the diagnostic value of the Psoriatic Arthritis Screening Evaluation (PASE) and Early Psoriatic Arthritis Screening Questionnaire (EARP) questionnaires in the ultrasonographic detection of enthesitis, synovitis, and tenosynovitis. A cross-sectional study was done in a total of 96 consecutive patients. Double blind clinical examination and echographic assessment were performed. A receiver-operating characteristic (ROC) model analysis for the questionnaires was established using echographic findings as reference variable. The optimal diagnostic point was determined following a Youden analysis model from the obtained data, calculating sensitivity and specificity along with predictive values, likelihood ratio, and diagnostic odds ratio. A logistic regression analysis was used to determine possible predictor variables of enthesitis, synovitis, and tenosynovitis. When enthesitis, synovitis, and tenosynovitis were considered as one outcome for the diagnostic study of the PASE or EARP questionnaire, there were no statistically significant differences among the score of the study groups and the rest of patients. The PASE and EARP tests had a diagnostic performance for enthesitis, synovitis, and tenosynovitis that followed the expected pattern when the prevalence of findings is low. In these cases, the tests increase their negative predictive value, being particularly interesting in ruling out the disease.


Subject(s)
Arthritis, Psoriatic/diagnosis , Psoriasis/complications , Surveys and Questionnaires , Synovitis/diagnosis , Tenosynovitis/diagnosis , Adult , Aged , Arthritis, Psoriatic/complications , Arthritis, Psoriatic/diagnostic imaging , Cross-Sectional Studies , Female , Humans , Male , Mass Screening , Middle Aged , Psoriasis/diagnostic imaging , Sensitivity and Specificity , Synovitis/complications , Synovitis/diagnostic imaging , Tenosynovitis/complications , Tenosynovitis/diagnostic imaging , Ultrasonography
9.
Reumatol. clín. (Barc.) ; 12(4): 201-205, jul.-ago. 2016.
Article in English | IBECS | ID: ibc-153623

ABSTRACT

Primary Sjögren syndrome (PSS) is a chronic inflammatory autoimmune disease. Interstitial lung disease (ILD) can be an extraglandular complication. Objective. To evaluate the clinical characteristics of patients diagnosed with PSS with ILD. Methods. Multicentre cohort study with 25 patients diagnosed with PSS and ILD. Data of PSS, prognostic factors, pulmonary involvement variables, complementary tests that suggest a worse diagnosis and treatment given were collected. EULAR index was measured for Sjögren's syndrome. Results. We identified 25 patients. In 15/25 the diagnosis of ILD was done before the diagnosis of PSS. The histopathological patterns found were: 12 NSIP, 5 UIP, 4 OP, 2 LIP. PFRs showed restrictive pattern. The majority of the patients received glucocorticoid therapy, antimalarial or immunosuppressive treatment. Conclusions. Patients affected with PSS must be screened to catch a precocious diagnosis of ILD. The majority of the patients were diagnosed of ILD before being diagnosed of PSS. Multicenter cohorts are increasingly demanded and a multidisciplinary management is needed (AU)


El síndrome de Sjögren primario (SSP) es una enfermedad inflamatoria autoinmune. La enfermedad pulmonar intersticial (EPI) puede ser una complicación extraglandular. Objetivo. Evaluar las características clínicas de los pacientes diagnosticados de SSP con EPI. Métodos. Estudio de cohortes multicéntrico con 25 pacientes diagnosticados de SSP y EPI. Se recopilaron datos propios del SSP, factores pronóstico, variables de medida de la afectación pulmonar, pruebas complementarias que sugieren un peor pronóstico, así como el tratamiento recibido. Se calculó el índice EULAR para el síndrome de Sjögren. Resultados. Se identificaron 25 pacientes. Quince de ellos fueron diagnosticados de EPI antes que de SSP. Los patrones histopatológicos encontrados fueron 12 con neumonía intersticial inespecífica, 5 con neumonía intersticial común, 4 con neumonía organizada, 2 con neumonía intersticial linfocítica. Las pruebas de función respiratoria mostraron un patrón restrictivo. La mayoría de los pacientes recibió un tratamiento con glucocorticoides, antipalúdicos o inmunodepresores. Conclusiones. Los pacientes afectados por SSP deben ser sometidos a pruebas para detectar un diagnóstico precoz de EPI. La mayoría de los pacientes fueron diagnosticados de EPI antes que de SSP. Los estudios de cohortes multicéntricos son cada vez más demandados y se precisa una gestión multidisciplinar (AU)


Subject(s)
Humans , Male , Female , Lung Diseases, Interstitial/complications , Lung Diseases, Interstitial/epidemiology , Lung Diseases, Interstitial , Sjogren's Syndrome/complications , Sjogren's Syndrome/epidemiology , Early Diagnosis , Sjogren's Syndrome/immunology , Sjogren's Syndrome/physiopathology , Sjogren's Syndrome , Prognosis , Bronchiolitis/complications , Bronchiectasis/complications , Bronchiectasis , Cohort Studies
10.
Reumatol Clin ; 12(4): 201-5, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-26573882

ABSTRACT

UNLABELLED: Primary Sjögren syndrome (PSS) is a chronic inflammatory autoimmune disease. Interstitial lung disease (ILD) can be an extraglandular complication. OBJECTIVE: To evaluate the clinical characteristics of patients diagnosed with PSS with ILD. METHODS: Multicentre cohort study with 25 patients diagnosed with PSS and ILD. Data of PSS, prognostic factors, pulmonary involvement variables, complementary tests that suggest a worse diagnosis and treatment given were collected. EULAR index was measured for Sjögren's syndrome. RESULTS: We identified 25 patients. In 15/25 the diagnosis of ILD was done before the diagnosis of PSS. The histopathological patterns found were: 12 NSIP, 5 UIP, 4 OP, 2 LIP. PFRs showed restrictive pattern. The majority of the patients received glucocorticoid therapy, antimalarial or immunosuppressive treatment. CONCLUSIONS: Patients affected with PSS must be screened to catch a precocious diagnosis of ILD. The majority of the patients were diagnosed of ILD before being diagnosed of PSS. Multicenter cohorts are increasingly demanded and a multidisciplinary management is needed.


Subject(s)
Lung Diseases, Interstitial/etiology , Sjogren's Syndrome/complications , Adult , Aged , Female , Follow-Up Studies , Humans , Lung Diseases, Interstitial/diagnosis , Lung Diseases, Interstitial/pathology , Male , Middle Aged , Prognosis , Retrospective Studies , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/pathology
11.
Clin Chem Lab Med ; 54(2): 293-303, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26088062

ABSTRACT

BACKGROUND: The aims of this study were to establish robust reference intervals and to investigate the factors influencing bone turnover markers (BTMs) in healthy premenopausal Spanish women. METHODS: A total of 184 women (35-45 years) from 13 centers in Catalonia were analyzed. Blood and second void urine samples were collected between 8 a.m. and 10 a.m. after an overnight fast. Serum procollagen type I amino-terminal propeptide (PINP) and serum cross-linked C-terminal telopeptide of type I collagen (CTX-I) were measured by two automated assays (Roche and IDS), bone alkaline phosphatase (bone ALP) by ELISA, osteocalcin (OC) by IRMA and urinary NTX-I by ELISA. PTH and 25-hydroxyvitamin D (25OHD) levels were measured. All participants completed a questionnaire on lifestyle factors. RESULTS: Reference intervals were: PINP: 22.7-63.1 and 21.8-65.5 µg/L, bone ALP: 6.0-13.6 µg/L, OC: 8.0-23.0 µg/L, CTX-I: 137-484 and 109-544 ng/L and NTX-I: 19.6-68.9 nM/mM. Oral contraceptive pills (OCPs) influenced PINP (p=0.007), and low body mass index (BMI) was associated with higher BTMs except for bone ALP. Women under 40 had higher median values of most BTMs. CTX-I was influenced by calcium intake (p=0.010) and PTH (p=0.007). 25OHD levels did not influence BTMs. Concordance between the two automated assays for PINP and particularly CTX-I was poor. CONCLUSIONS: Robust reference intervals for BTMs in a Southern European country are provided. The effects of OCPs and BMI on their levels are significant, whilst serum 25OHD levels did not influence BTMs. Age, calcium intake, BMI and PTH influenced CTX-I. The two automated assays for measuring PINP and CTX-I are not interchangeable.


Subject(s)
Biomarkers/blood , Bone Remodeling , Enzyme-Linked Immunosorbent Assay , Adult , Alkaline Phosphatase/analysis , Alkaline Phosphatase/standards , Biomarkers/urine , Body Mass Index , Collagen Type I/blood , Collagen Type I/standards , Enzyme-Linked Immunosorbent Assay/standards , Female , Humans , Middle Aged , Osteocalcin/analysis , Osteocalcin/standards , Parathyroid Hormone/analysis , Parathyroid Hormone/standards , Peptide Fragments/blood , Peptide Fragments/standards , Peptide Fragments/urine , Peptides/blood , Peptides/standards , Premenopause , Procollagen/blood , Procollagen/standards , Procollagen/urine , Reference Values , Vitamin D/analogs & derivatives , Vitamin D/analysis , Vitamin D/standards
12.
Enferm Clin ; 23(4): 164-9, 2013.
Article in Spanish | MEDLINE | ID: mdl-23916813

ABSTRACT

OBJECTIVES: The aims of this study are to evaluate the level of fear of post-injection pain prior to the administration, the difficulty in handling the device, and the level of satisfaction of patients using a pre-filled syringe versus an etanercept pen, as well as to evaluate the usefulness of the training given by nursing staff prior to starting with the pen, and the preferences of patients after using both devices. METHOD: A prospective study was designed to follow-up a cohort of patients during a 6 months period. The data was collected using questionnaires and analyzed with SPSS 18.00. Rank and McNemar tests were performed. Statistical significance was pre-set at an α level of 0.05. RESULTS: A total of 29 patients were included, of whom 69% female, and with a mean age 52.5±10.9 years. Of these, 48% had rheumatoid arthritis, 28% psoriatic arthritis, 21% ankylosing spondylitis, and 3% undifferentiated spondyloarthropathy. There were no statistically significant differences either with the fear or pain or handling of the device between the syringe and the pen (P=.469; P=.812; P=.169 respectively). At 6 months, 59% of patients referred to being satisfied or very satisfied with the pen. Almost all (93%) found useful or very useful the training given by nursing staff prior to using the pen, and 55% preferred the pen over the pre-filled syringe. CONCLUSIONS: The etanercept pen is another subcutaneous device option for patients with chronic arthritis. According to the present study, nursing educational workshops before starting this therapy are recommended.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Arthritis/drug therapy , Immunoglobulin G/administration & dosage , Patient Preference , Receptors, Tumor Necrosis Factor/administration & dosage , Chronic Disease , Education, Nursing , Equipment Design , Etanercept , Female , Humans , Male , Middle Aged , Prospective Studies , Syringes
13.
Enferm. clín. (Ed. impr.) ; 23(4): 164-169, jul.-agos. 2013. tab, ima
Article in Spanish | IBECS | ID: ibc-114838

ABSTRACT

Objetivos Evaluar el temor previo a la administración, dolor postinyección, la dificultad de manejo y el grado de satisfacción de jeringa versus pluma de etanercept subcutáneo. Monitorizar la utilidad de la formación proporcionada por enfermería previa al inicio de la pluma y las preferencias de los pacientes tras haber utilizado ambos dispositivos. Método Estudio prospectivo de una cohorte de pacientes durante 6 meses. La recogida de datos se hizo a través de cuestionarios. Análisis estadístico: SPSS 18.00. Se utilizaron la prueba de rangos y la de McNemar, considerándose como nivel de significación un α = 0,05. Resultados Se incluyeron 29 sujetos, 69% mujeres, con una edad media de 52,5 ± 10,9 años. El 48% eran artritis reumatoide, el 28% artritis psoriásica, el 21% espondilitis anquilosante y el 3% espondiloartropatía indiferenciada. Comparando el dispositivo de jeringa con el de pluma, no se encontraron diferencias estadísticamente significativas ni en el temor, ni en el dolor, ni en la dificultad de manejo del dispositivo (p = 0,469; p = 0,812 y p = 0,169 respectivamente). A los 6 meses, el 59% de los pacientes refirieron estar satisfechos o muy satisfechos con la pluma, el 93% encontraron el taller de enfermería útil o muy útil y el 55% prefirieron la pluma. Conclusiones La pluma de etanercept es otra opción de dispositivo subcutáneo para los pacientes con artritis crónica. El presente trabajo sugiere que los talleres educacionales por enfermería previos al inicio de dicha terapia subcutánea son recomendables (AU)


Objectives The aims of this study are to evaluate the level of fear of post-injection pain prior to the administration, the difficulty in handling the device, and the level of satisfaction of patients using a pre-filled syringe versus an etanercept pen, as well as to evaluate the usefulness of the training given by nursing staff prior to starting with the pen, and the preferences of patients after using both devices. Method A prospective study was designed to follow-up a cohort of patients during a 6 months period. The data was collected using questionnaires and analyzed with SPSS 18.00. Rank and McNemar tests were performed. Statistical significance was pre-set at an α level of 0.05. Results A total of 29 patients were included, of whom 69% female, and with a mean age 52.5 ± 10.9 years. Of these, 48% had rheumatoid arthritis, 28% psoriatic arthritis, 21% ankylosing spondylitis, and 3% undifferentiated spondyloarthropathy. There were no statistically significant differences either with the fear or pain or handling of the device between the syringe and the pen (P = .469; P = .812; P = .169 respectively). At 6 months, 59% of patients referred to being satisfied or very satisfied with the pen. Almost all (93%) found useful or very useful the training given by nursing staff prior to using the pen, and 55% preferred the pen over the pre-filled syringe. Conclusions The etanercept pen is another subcutaneous device option for patients with chronic arthritis. According to the present study, nursing educational workshops before starting this therapy are recommended (AU)


Subject(s)
Humans , Injections , Arthritis/drug therapy , Spondylitis, Ankylosing/drug therapy , Arthritis, Rheumatoid/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Prospective Studies , Patient Satisfaction
14.
Reumatol. clín. (Barc.) ; 9(4): 246-247, jul.-ago. 2013.
Article in Spanish | IBECS | ID: ibc-113683

ABSTRACT

El síndrome de Sweet o dermatosis neutrofílica febril aguda es una enfermedad sistémica de etiología desconocida, caracterizada por la aparición de lesiones cutáneas producidas por un infiltrado dérmico neutrofílico, fiebre y leucocitosis periférica. Puede estar asociado a enfermedades hematológicas, incluida la leucemia, inmunológicas como la artritis reumatoide o presentarse de forma aislada. Las mielodisplasias son trastornos hematológicos caracterizados por una o más citopenias secundarias a la disfunción de la médula ósea. Se presenta el caso de un paciente con síndrome de Sweet asociado a un síndrome mielodisplásico que ha seguido tratamiento con glucocorticoides y no ha presentado una buena evolución clínica. Se discuten los diferentes tratamientos de estas enfermedades porque en la mayoría de las ocasiones los glucocorticoides, que son el tratamiento de elección en el síndrome de Sweet, pueden ser insuficientes (AU)


Sweet’s syndrome or acute neutrophilic febrile dermatosis is a systemic disease of unknown etiology characterized by the appearance of skin lesions produced by a neutrophilic dermal infiltrate, fever and peripheral leukocytosis. It may be associated with hematologic diseases, including leukemia, with immune diseases as rheumatoid arthritis, or can occur in isolation. The myelodysplasias are hematological disorders characterized by one or more cytopenias secondary to bone marrow dysfunction. We present the case of a patient with Sweet’s syndrome associated with myelodysplastic syndrome and treated with glucocorticoids who did not present a good clinical outcome. We discuss the different treatment of these diseases because in most cases glucocorticoids, which are the treatment of choice in Sweet’s syndrome, may be insufficient (AU)


Subject(s)
Humans , Male , Middle Aged , Sweet Syndrome/complications , Sweet Syndrome/diagnosis , Sweet Syndrome/drug therapy , Neural Tube Defects/complications , Arthritis/complications , Arthritis/diagnosis , Sweet Syndrome/physiopathology , Skin Diseases/complications , Skin Diseases/diagnosis , Skin Diseases/drug therapy , Arthritis/drug therapy , Arthritis/physiopathology
15.
Hepatology ; 58(6): 2070-8, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23686738

ABSTRACT

UNLABELLED: Osteoporosis resulting in bone fractures is a complication in patients with primary biliary cirrhosis (PBC). Once-weekly alendronate improves bone mass and is well tolerated in these patients, but there is a concern because of poor compliance. Therefore, the efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) were compared in a randomized, 2-year study in 42 postmenopausal women with PBC and osteoporosis. Bone mineral density (BMD) of the lumbar spine and proximal femur (by DXA), liver function, and bone markers were measured at entry and every 6 months over 2 years. Adherence to therapy was assessed by the Morisky-Green score. At enrollment, the two groups were similar with respect to age, BMD, severity of cholestasis, previous fractures, and bone markers. Thirty-three patients, 14 in the ibandronate group and 19 in the alendronate group, completed the trial. At 2 years both treatments resulted in a significant increase in BMD at the lumbar spine (from 0.875 ± 0.025 to 0.913 ± 0.026 g/cm(2), P < 0.001 with alendronate, and from 0.898 ± 0.024 to 0.949 ± 0.027 g/cm(2), P < 0.001 with ibandronate). The mean percentage change was 4.5% and 5.7%, respectively (P = not significant). BMD increased at the total hip by 2.0% and 1.2%, respectively. Changes in bone markers were similar in both groups and one patient with alendronate developed a new vertebral fracture. Adherence to therapy was higher with ibandronate (P = 0.009). Neither treatment impaired liver function or cholestasis. CONCLUSION: Both regimens, weekly alendronate and monthly ibandronate, improve bone mass and are comparable in safety for osteoporosis therapy in patients with PBC, although adherence is higher with the monthly regimen. Further larger studies are needed to assess fracture prevention.


Subject(s)
Fractures, Bone/prevention & control , Liver Cirrhosis, Biliary/drug therapy , Osteoporosis, Postmenopausal/drug therapy , Administration, Oral , Aged , Alendronate/administration & dosage , Bone Density , Diphosphonates , Drug Administration Schedule , Female , Humans , Ibandronic Acid , Liver Cirrhosis, Biliary/complications , Middle Aged , Osteoporosis, Postmenopausal/complications , Patient Compliance , Treatment Outcome
16.
Reumatol Clin ; 9(4): 246-7, 2013.
Article in English, Spanish | MEDLINE | ID: mdl-22749728

ABSTRACT

Sweet's syndrome or acute neutrophilic febrile dermatosis is a systemic disease of unknown etiology characterized by the appearance of skin lesions produced by a neutrophilic dermal infiltrate, fever and peripheral leukocytosis. It may be associated with hematologic diseases, including leukemia, with immune diseases as rheumatoid arthritis, or can occur in isolation. The myelodysplasias are hematological disorders characterized by one or more cytopenias secondary to bone marrow dysfunction. We present the case of a patient with Sweet's syndrome associated with myelodysplastic syndrome and treated with glucocorticoids who did not present a good clinical outcome. We discuss the different treatment of these diseases because in most cases glucocorticoids, which are the treatment of choice in Sweet's syndrome, may be insufficient.


Subject(s)
Myelodysplastic Syndromes/complications , Sweet Syndrome/complications , Aged , Humans , Male
17.
Med. clín (Ed. impr.) ; 139(14): 626-630, dic. 2012. tab
Article in Spanish | IBECS | ID: ibc-109623

ABSTRACT

Fundamento y objetivo: Las fracturas vertebrales (FV) son un factor de riesgo mayor para desarrollar nuevas fracturas. Es importante identificar las características clínicas y las alteraciones en las pruebas de laboratorio relacionadas con su desarrollo. El objetivo de este estudio fue analizar las características clínicas y alteraciones analíticas relacionadas con la presencia de FV radiológicas en mujeres posmenopáusicas con osteoporosis. Pacientes y método. En 204 mujeres (edad media [DE] de 64,9 [10] años) referidas a una consulta de Reumatología se determinaron pruebas bioquímicas y hormonales del metabolismo mineral, densidad mineral ósea (DMO) y radiografías de columna dorso lumbar. Resultados: Un 28% tenían FV. Al comparar las mujeres con y sin FV, aquellas con FV eran de mayor edad (media de 71,9 [10] frente a 61,8 [6,8] años, p<0,001), menor estatura (media de 152 [2,7] frente a 155 [2,6] cm, p=0,01), menor DMO en fémur total (media de puntuación en la escala T de -2,2 [0,91] frente a -1,9 [0,8], p=0,041), mayor prevalencia de fracturas no vertebrales (38 frente a 30%, p=0,04) y de valores bajos de 25-hidroxivitamina D (25-OH-D) (69 frente a 53%, p<0,05). En el análisis de regresión logística, la edad y la DMO en fémur total fueron factores predictores independientes para FV. Las pacientes mayores de 65 años presentaron una mayor frecuencia de FV (47 frente a 12%, p<0,0001). Además, una puntuación en la escala T menor de -2,5 en fémur total se asoció con un incremento de riesgo de FV (odds ratio 2,5; intervalo de confianza del 95% 1,2-4,9). Conclusiones: A partir de los 65 años casi la mitad de las mujeres posmenopáusicas con osteoporosis referidas a una consulta especializada tienen FV y la mayoría de ellas presentan un déficit de vitamina D. En este grupo de pacientes es aconsejable realizar una radiografía de columna y determinar los valores séricos de 25-OH-D, ya que van a determinar la actitud terapéutica (AU)


Background and objective: Vertebral fractures (VF) are a major risk factor for the development of furtherfractures. Therefore, it is important to identify clinical risk factors and laboratory abnormalities relatedto VF. We aimed to analyse clinical and biochemical alterations related to the presence of radiological VFin postmenopausal women with osteoporosis. Patients and methods: Two-hundred and four postmenopausal women with osteoporosis (aged 64,9 [10]years) who were referred to an outpatient Rheumatology Unit were prospectively included. Bonemineral density (BMD), spine X-ray, and laboratory tests were performed in all participants beforet reatment. Results: Twenty-eight per cent of patients had VF. Comparing women with and without VF, those with fractures were older (71.9 [10] vs 61.8 [8,6], P < .001), had lower stature (152 [7.2] vs 155 [6.2], P = .01), lower total hip T-score values (-2.2 [0,9] vs -1.9 [0.8], P = .041), higher prevalence of non-VF (38 vs 30%,P = .04) and a higher prevalence of low serum 25(OH)D levels (69 vs 53%, P < .05). In logistic regression analysis, age and BMD at the total hip were independent predictors of VF. Patients over 65 presented ahigher frequency of VF (47 vs 12%, P < .0001). In addition, a T-score lower than -2,5 at the total hip was associated with an increased risk of VF (OR 2.5; 95% CI 1.2-4.9).Conclusions: Over the age of 65 nearly half of the postmenopausal women with osteoporosis have VF and a higher prevalence of low 25(OH)D serum measurements. Spinal X-ray and 25(OH)D serum measurements are especially indicated in this group of women since it influences the therapeutic approach (AU)


Subject(s)
Humans , Female , Middle Aged , Aged , Aged, 80 and over , Osteoporotic Fractures/epidemiology , Spinal Fractures/epidemiology , Osteoporosis/complications , Vitamin D Deficiency/complications , Risk Factors , Cross-Sectional Studies
18.
Med Clin (Barc) ; 139(14): 626-30, 2012 Dec 08.
Article in Spanish | MEDLINE | ID: mdl-22459575

ABSTRACT

BACKGROUND AND OBJECTIVE: Vertebral fractures (VF) are a major risk factor for the development of further fractures. Therefore, it is important to identify clinical risk factors and laboratory abnormalities related to VF. We aimed to analyse clinical and biochemical alterations related to the presence of radiological VF in postmenopausal women with osteoporosis. PATIENTS AND METHODS: Two-hundred and four postmenopausal women with osteoporosis (aged 64,9 [10] years) who were referred to an outpatient Rheumatology Unit were prospectively included. Bone mineral density (BMD), spine X-ray, and laboratory tests were performed in all participants before treatment. RESULTS: Twenty-eight per cent of patients had VF. Comparing women with and without VF, those with fractures were older (71.9 [10] vs 61.8 [8,6], P<.001), had lower stature (152 [7.2] vs 155 [6.2], P=.01), lower total hip T-score values (-2.2 [0,9] vs -1.9 [0.8], P=.041), higher prevalence of non-VF (38 vs 30%, P=.04) and a higher prevalence of low serum 25(OH)D levels (69 vs 53%, P<.05). In logistic regression analysis, age and BMD at the total hip were independent predictors of VF. Patients over 65 presented a higher frequency of VF (47 vs 12%, P<.0001). In addition, a T-score lower than -2,5 at the total hip was associated with an increased risk of VF (OR 2.5; 95% CI 1.2-4.9). CONCLUSIONS: Over the age of 65 nearly half of the postmenopausal women with osteoporosis have VF and a higher prevalence of low 25(OH)D serum measurements. Spinal X-ray and 25(OH)D serum measurements are especially indicated in this group of women since it influences the therapeutic approach.


Subject(s)
Osteoporosis, Postmenopausal/complications , Osteoporotic Fractures/etiology , Spinal Fractures/etiology , Aged , Cross-Sectional Studies , Female , Humans , Middle Aged , Prospective Studies , Risk Factors
19.
Reumatol. clín. (Barc.) ; 7(6): 357-379, nov.-dic. 2011. tab
Article in Spanish | IBECS | ID: ibc-91554

ABSTRACT

Objetivo. Dado el creciente avance en el diagnóstico como evaluación y tratamiento de la osteoporosis, y la incorporación de nuevas herramientas y medicamentos, desde la Sociedad Española de Reumatología (SER) se ha impulsado el desarrollo de recomendaciones basadas en la mejor evidencia posible. Estas deben de servir de referencia para reumatólogos y otros profesionales de la salud implicados en el tratamiento de pacientes con osteoporosis. Métodos. Las recomendaciones se emitieron siguiendo la metodología de grupos nominales. El nivel de evidencia y el grado de recomendación se clasificaron según el modelo del Center for Evidence Based Medicine de Oxford y el grado de acuerdo se extrajo por técnica Delphi. Se utilizó toda la información de consensos previos y guías de práctica clínica disponibles. Resultados. Se realizan recomendaciones sobre el diagnóstico, la evaluación y el tratamiento en pacientes con osteoporosis. Estas recomendaciones incluyen la osteoporosis secundaria a glucocorticoides, la osteoporosis premenopáusica y la del varón. Conclusiones. Se presentan las recomendaciones SER sobre el diagnóstico, la evaluación y el manejo de pacientes con osteoporosis (AU)


Objective. Due to increasing improvement in the diagnosis, evaluation and management of osteoporosis and the development of new tools and drugs, the Spanish Society of Rheumatology (SER) has promoted the development of recommendations based on the best evidence available. These recommendations should be a reference to rheumatologists and other health professionals involved in the treatment of patients with osteoporosis. Methods. Recommendations were developed following a nominal group methodology and based on a systematic review. The level of evidence and degree of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. Evidence from previous consensus and available clinical guidelines was used. Results. We have produced recommendations on diagnosis, evaluation and management of osteoporosis. These recommendations include the glucocorticoid-induced osteoporosis, premenopausal and male osteoporosis. Conclusions. We present the SER recommendations related to the biologic therapy risk management (AU)


Subject(s)
Humans , Male , Female , Societies, Medical/trends , Societies, Medical , Rheumatology/methods , Rheumatology/trends , Osteoporosis/epidemiology , Evidence-Based Medicine/methods , Evidence-Based Medicine/trends , Rheumatology/education , Rheumatology/ethics , Rheumatic Diseases/epidemiology
20.
Reumatol Clin ; 7(6): 357-79, 2011.
Article in Spanish | MEDLINE | ID: mdl-22078694

ABSTRACT

OBJECTIVE: Due to increasing improvement in the diagnosis, evaluation and management of osteoporosis and the development of new tools and drugs, the Spanish Society of Rheumatology (SER) has promoted the development of recommendations based on the best evidence available. These recommendations should be a reference to rheumatologists and other health professionals involved in the treatment of patients with osteoporosis. METHODS: Recommendations were developed following a nominal group methodology and based on a systematic review. The level of evidence and degree of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique. Evidence from previous consensus and available clinical guidelines was used. RESULTS: We have produced recommendations on diagnosis, evaluation and management of osteoporosis. These recommendations include the glucocorticoid-induced osteoporosis, premenopausal and male osteoporosis. CONCLUSIONS: We present the SER recommendations related to the biologic therapy risk management.


Subject(s)
Osteoporosis , Absorptiometry, Photon , Bone Density , Bone Density Conservation Agents/therapeutic use , Female , Humans , Male , Osteoporosis/complications , Osteoporosis/diagnosis , Osteoporosis/drug therapy , Osteoporotic Fractures/diagnosis , Osteoporotic Fractures/etiology , Osteoporotic Fractures/therapy , Risk Factors , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...